Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient

Pluronic P85

Elena V. Batrakova, David Lee Kelly, Shu Li, Yili Li, Zhihui Yang, Li Xiao, Daria Y. Alakhova, Simon Sherman, Valery Yu Alakhov, Alexander V. Kabanov

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Polymer therapeutics has emerged as a new clinical option for the treatment of human diseases. However, little is known about pharmacogenetic responses to drugs formulated with polymers. In this study, we demonstrate that a formulation containing the block copolymer Pluronic P85 and antineoplastic drug doxorubicin (Dox) prevents the development of multidrug resistance in the human breast carcinoma cell line, MCF7. Specifically, MCF7 cells cultured in the presence of Pluronic were unable to stably grow in concentrations of Dox that exceeded 10 ng of Dox/mL of culture medium. In sharp contrast, MCF7 cells cultured in the absence of the block copolymer resulted in the selection and stable growth of cells that tolerated a 1000 times higher concentration of the drug (10 000 ng of Dox/mL of culture medium). Detailed characterization of the isolated sublines demonstrated that those cells selected in the polymer-drug formulation did not show amplification of the MDR1 gene, likely resulting in their high sensitivity to the drug. Conversely, cells selected with Dox alone showed an elevated level in the expression of the MDR1 gene along with a corresponding increase in the expression level of the drug efflux transporter, Pgp, and likely contributing to the high resistance of the cells to Dox. Global analysis of the expression profiles of 20K genes by DNA microarray revealed that the use of Pluronic in combination with Dox drastically changed the direction and magnitude of the genetic response of the tumor cells to Dox and may potentially enhance therapeutic outcomes. Overall, this study reinforces the need for a thorough assessment of pharmacogenomic effects of polymer therapeutics.

Original languageEnglish (US)
Pages (from-to)113-123
Number of pages11
JournalMolecular Pharmaceutics
Volume3
Issue number2
DOIs
StatePublished - Mar 1 2006

Fingerprint

Poloxamer
Excipients
Doxorubicin
Polymers
Breast Neoplasms
Pharmacogenetics
MCF-7 Cells
Pharmaceutical Preparations
Culture Media
Drug Compounding
Gene Amplification
Multiple Drug Resistance
Therapeutic Uses
Oligonucleotide Array Sequence Analysis
Transcriptome
Antineoplastic Agents
Therapeutics
Gene Expression
Cell Line
Growth

Keywords

  • Multidrug resistance
  • P-glycoprotein
  • Pluronic
  • Poloxamer
  • Polymer genomics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient : Pluronic P85. / Batrakova, Elena V.; Kelly, David Lee; Li, Shu; Li, Yili; Yang, Zhihui; Xiao, Li; Alakhova, Daria Y.; Sherman, Simon; Alakhov, Valery Yu; Kabanov, Alexander V.

In: Molecular Pharmaceutics, Vol. 3, No. 2, 01.03.2006, p. 113-123.

Research output: Contribution to journalArticle

Batrakova, Elena V. ; Kelly, David Lee ; Li, Shu ; Li, Yili ; Yang, Zhihui ; Xiao, Li ; Alakhova, Daria Y. ; Sherman, Simon ; Alakhov, Valery Yu ; Kabanov, Alexander V. / Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient : Pluronic P85. In: Molecular Pharmaceutics. 2006 ; Vol. 3, No. 2. pp. 113-123.
@article{238c72fc0941465bb0f7f0be40512e6c,
title = "Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85",
abstract = "Polymer therapeutics has emerged as a new clinical option for the treatment of human diseases. However, little is known about pharmacogenetic responses to drugs formulated with polymers. In this study, we demonstrate that a formulation containing the block copolymer Pluronic P85 and antineoplastic drug doxorubicin (Dox) prevents the development of multidrug resistance in the human breast carcinoma cell line, MCF7. Specifically, MCF7 cells cultured in the presence of Pluronic were unable to stably grow in concentrations of Dox that exceeded 10 ng of Dox/mL of culture medium. In sharp contrast, MCF7 cells cultured in the absence of the block copolymer resulted in the selection and stable growth of cells that tolerated a 1000 times higher concentration of the drug (10 000 ng of Dox/mL of culture medium). Detailed characterization of the isolated sublines demonstrated that those cells selected in the polymer-drug formulation did not show amplification of the MDR1 gene, likely resulting in their high sensitivity to the drug. Conversely, cells selected with Dox alone showed an elevated level in the expression of the MDR1 gene along with a corresponding increase in the expression level of the drug efflux transporter, Pgp, and likely contributing to the high resistance of the cells to Dox. Global analysis of the expression profiles of 20K genes by DNA microarray revealed that the use of Pluronic in combination with Dox drastically changed the direction and magnitude of the genetic response of the tumor cells to Dox and may potentially enhance therapeutic outcomes. Overall, this study reinforces the need for a thorough assessment of pharmacogenomic effects of polymer therapeutics.",
keywords = "Multidrug resistance, P-glycoprotein, Pluronic, Poloxamer, Polymer genomics",
author = "Batrakova, {Elena V.} and Kelly, {David Lee} and Shu Li and Yili Li and Zhihui Yang and Li Xiao and Alakhova, {Daria Y.} and Simon Sherman and Alakhov, {Valery Yu} and Kabanov, {Alexander V.}",
year = "2006",
month = "3",
day = "1",
doi = "10.1021/mp050050g",
language = "English (US)",
volume = "3",
pages = "113--123",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "2",

}

TY - JOUR

T1 - Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient

T2 - Pluronic P85

AU - Batrakova, Elena V.

AU - Kelly, David Lee

AU - Li, Shu

AU - Li, Yili

AU - Yang, Zhihui

AU - Xiao, Li

AU - Alakhova, Daria Y.

AU - Sherman, Simon

AU - Alakhov, Valery Yu

AU - Kabanov, Alexander V.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Polymer therapeutics has emerged as a new clinical option for the treatment of human diseases. However, little is known about pharmacogenetic responses to drugs formulated with polymers. In this study, we demonstrate that a formulation containing the block copolymer Pluronic P85 and antineoplastic drug doxorubicin (Dox) prevents the development of multidrug resistance in the human breast carcinoma cell line, MCF7. Specifically, MCF7 cells cultured in the presence of Pluronic were unable to stably grow in concentrations of Dox that exceeded 10 ng of Dox/mL of culture medium. In sharp contrast, MCF7 cells cultured in the absence of the block copolymer resulted in the selection and stable growth of cells that tolerated a 1000 times higher concentration of the drug (10 000 ng of Dox/mL of culture medium). Detailed characterization of the isolated sublines demonstrated that those cells selected in the polymer-drug formulation did not show amplification of the MDR1 gene, likely resulting in their high sensitivity to the drug. Conversely, cells selected with Dox alone showed an elevated level in the expression of the MDR1 gene along with a corresponding increase in the expression level of the drug efflux transporter, Pgp, and likely contributing to the high resistance of the cells to Dox. Global analysis of the expression profiles of 20K genes by DNA microarray revealed that the use of Pluronic in combination with Dox drastically changed the direction and magnitude of the genetic response of the tumor cells to Dox and may potentially enhance therapeutic outcomes. Overall, this study reinforces the need for a thorough assessment of pharmacogenomic effects of polymer therapeutics.

AB - Polymer therapeutics has emerged as a new clinical option for the treatment of human diseases. However, little is known about pharmacogenetic responses to drugs formulated with polymers. In this study, we demonstrate that a formulation containing the block copolymer Pluronic P85 and antineoplastic drug doxorubicin (Dox) prevents the development of multidrug resistance in the human breast carcinoma cell line, MCF7. Specifically, MCF7 cells cultured in the presence of Pluronic were unable to stably grow in concentrations of Dox that exceeded 10 ng of Dox/mL of culture medium. In sharp contrast, MCF7 cells cultured in the absence of the block copolymer resulted in the selection and stable growth of cells that tolerated a 1000 times higher concentration of the drug (10 000 ng of Dox/mL of culture medium). Detailed characterization of the isolated sublines demonstrated that those cells selected in the polymer-drug formulation did not show amplification of the MDR1 gene, likely resulting in their high sensitivity to the drug. Conversely, cells selected with Dox alone showed an elevated level in the expression of the MDR1 gene along with a corresponding increase in the expression level of the drug efflux transporter, Pgp, and likely contributing to the high resistance of the cells to Dox. Global analysis of the expression profiles of 20K genes by DNA microarray revealed that the use of Pluronic in combination with Dox drastically changed the direction and magnitude of the genetic response of the tumor cells to Dox and may potentially enhance therapeutic outcomes. Overall, this study reinforces the need for a thorough assessment of pharmacogenomic effects of polymer therapeutics.

KW - Multidrug resistance

KW - P-glycoprotein

KW - Pluronic

KW - Poloxamer

KW - Polymer genomics

UR - http://www.scopus.com/inward/record.url?scp=33646348476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646348476&partnerID=8YFLogxK

U2 - 10.1021/mp050050g

DO - 10.1021/mp050050g

M3 - Article

VL - 3

SP - 113

EP - 123

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 2

ER -